Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study

Can Fite Biopharma

02/09/2026 12:38

Updates
** U.S.-listed shares of Can-Fite BioPharma CANF.TA rise 18.8% to $3.91 premarket
** Co says overall survival in its ongoing late-stage study testing its liver cancer drug appears longer than anticipated
** The late-stage study is testing namodenoson in patients with advanced hepatocellular carcinoma, a type of liver cancer 
** Due to the longer-than-anticipated survival observed in the study population, co is evaluating an earlier timing for the study's planned interim analysis, it says
** The survival data reflect the pooled, blinded study population and include patients receiving both namodenoson and placebo; no conclusions on namodenoson's efficacy can be drawn at this stage, CANF says
** The drug is also being tested to potentially treat pancreatic cancer and a type of fatty liver disease 
** Up to last close, stock has fallen 83.3% YTD

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))